Results 211 to 220 of about 1,512,902 (358)

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Repurposing a Drug Targeting Inflammatory Bowel Disease for Lowering Hypertension. [PDF]

J Am Heart Assoc, 2022
Mei X, Mell B, Manandhar I, Aryal S, Tummala R, Kyoung J, Yang T, Joe B.   +7 more
europepmc   +1 more source

Characterization of four novel bacteriophages targeting multi-drug resistant Klebsiella pneumoniae strains of sequence type 147 and 307 [PDF]

Greta Ponsecchi, Tommaso Olimpieri, Noemi Poerio, Alberto Antonelli, Marco Coppi, Gustavo Di Lallo, Mariangela Gentile, Eugenio Paccagnini, Pietro Lupetti, Claudio Lubello, Gian María Rossolini, Maurizio Fraziano, Marco Maria D’Andrea   +12 more
openalex   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management. [PDF]

Curr Neuropharmacol
Khan KA, Esa M, Kamal Z, Ullah B, Perry G, Kamal S, Ahmad S, Hussain H, Ullah A, Shafique M.   +9 more
europepmc   +1 more source

Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis. [PDF]

Int J Mol Sci, 2023
Lukovic D, Hasimbegovic E, Winkler J, Mester-Tonczar J, Müller-Zlabinger K, Han E, Spannbauer A, Traxler-Weidenauer D, Bergler-Klein J, Pavo N, Goliasch G, Batkai S, Thum T, Zannad F, Gyöngyösi M.   +14 more
europepmc   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Defining proteoform-specific interactions for drug targeting in a native cell signalling environment. [PDF]

Nat Chem
Lutomski CA, Bennett JL, El-Baba TJ, Wu D, Hinkle JD, Burnap SA, Liko I, Mullen C, Syka JEP, Struwe WB, Robinson CV.   +10 more
europepmc   +1 more source

Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. [PDF]

Nanotheranostics, 2023
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S, Kennerley AJ, Wood D, Moorehead R, Hadfield C, Rominiyi O, Griffin J, Collis SJ, Hyde S, Crossley M, Paley M, Muthana M.   +20 more
europepmc   +1 more source

Correction: Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis

, 2016
Kayode K. Ojo, Ranae M. Ranade, Zhongsheng Zhang, David M. Dranow, Janette B. Myers, Ryan Choi, Steve Nakazawa Hewitt, Thomas E. Edwards, D.R. Davies, Donald D. Lorimer, Stephen M. Boyle, Lynn K. Barrett, Frederick S. Buckner, Erkang Fan, Wesley C. Van Voorhis   +14 more
openalex   +2 more sources